Harpoon is a clinical-stage immunotherapy company based in South San Francisco developing a novel class of T cell engagers via its TriTAC and ProTriTAC platforms. Its lead product candidate, HPN424, is in a Phase 1 clinical trial for metastatic castration-resistant prostate cancer (mCRPC). The company plans to initiate Phase 1 trials in 2019 for HPN536 (mesothelin-targeting TriTAC) and HPN217 (BCMA-targeting TriTAC) and to advance its first ProTriTAC candidate into IND-enabling studies in 2019. Harpoon intends to use the newly raised capital to further advance these immunotherapy programs. The company’s approach is designed to harness the body’s immune system to target cancer and other diseases. No operating metrics (revenue/users) were reported in the article. Harpoon Therapeutics develops tri-specific T-cell activating constructs (TriTAC™) as antibody-based biologics to recruit and activate T cells against cancer. Its lead clinical candidate, HPN424, is a PSMA-targeting TriTAC™ in development for metastatic prostate cancer and was expected to enter Phase 1 trials in 2018. The company plans to move two lead programs into clinical trials and to expand its pipeline through discovery and partnering initiatives. Harpoon is also increasing commitment to additional therapeutic platforms, including constructs activated by proteases in the tumor microenvironment. The company was founded by Patrick Baeuerle, PhD, and MPM Capital and is based in South San Francisco. Financially, Harpoon completed a $45M Series B financing to advance its TriTAC platform and pipeline.

Total raised

$115M

Funding rounds

2

Latest round

Series C

Latest activity

Nov 2018